ProQR Therapeutics N.V.

Historical 13F Holders

Symbol
PRQR
CUSIP
N71542109
All holders as of
Q2 2026
Type
Equity
Class
SHS EURO
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for N71542109 since 12/18/2024, newest first.

Filer % of Class Filed
Aberdeen Group plc 13G
6.3% 7/29/2026
Event 6/30/2026
Van Herk Investments B.V. 13D/A Amendment 7
10.9% 7/29/2026
Event 7/27/2026
ELI LILLY & Co 13G/A Amendment 2 15.6% 7/24/2026
Event 6/26/2026
Privium Fund Management B.V. 13G/A Amendment 1
5.2% 7/15/2026
Event 7/15/2026
Van Herk Investments B.V. 13D/A Amendment 6
10.9% 6/30/2026
Event 6/26/2026
Van Herk Investments B.V. 13D/A Amendment 5
14.6% 6/3/2026
Event 6/2/2026
Van Herk Investments B.V. 13D/A Amendment 4
14.6% 2/6/2026
Event 2/5/2026
Privium Fund Management B.V. 13G
5.2% 1/20/2026
Event 12/11/2025
Van Herk Investments B.V. 13D/A Amendment 3
13.6% 9/30/2025
Event 9/29/2025
Van Herk Investments B.V. 13D/A Amendment 2
12.6% 9/4/2025
Event 9/3/2025
Van Herk Investments B.V. 13D/A Amendment 1
11.6% 8/20/2025
Event 8/19/2025
Adage Capital Management, L.P. 13G/A Amendment 2
6.3% 8/12/2025
Event 6/30/2025
Van Herk Investments B.V. 13D
10.9% 5/28/2025
Event 5/23/2025
Adage Capital Management, L.P. 13G/A Amendment 1
7.7% 5/12/2025
Event 3/31/2025
Van Herk Investments B.V. 13G/A Amendment 3
10.9% 2/14/2025
Event 12/31/2024
Adage Capital Management, L.P. 13G
9.3% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 191 k $317 k
2026 Q2 70 60.7 M $113 M
2026 Q1 70 35.1 M $56.8 M
2025 Q4 67 37.2 M $75.1 M
2025 Q3 65 37.5 M $80.0 M
2025 Q2 65 40.6 M $82.6 M
2025 Q1 69 41.3 M $54.9 M
2024 Q4 83 44.4 M $117 M
2024 Q3 53 17.4 M $31.7 M
2024 Q2 54 17.4 M $28.8 M
2024 Q1 56 17.5 M $40.1 M
2023 Q4 52 18.5 M $37.2 M
2023 Q3 47 18.7 M $24.1 M
2023 Q2 55 21.1 M $34.2 M
2023 Q1 60 22.3 M $47.5 M
2022 Q4 53 16.7 M $60.0 M
2022 Q3 51 21.3 M $15.9 M
2022 Q2 57 22.1 M $17.2 M
2022 Q1 71 31.9 M $28.9 M
2021 Q4 84 45.5 M $365 M
2021 Q3 74 39.8 M $333 M
2021 Q2 67 38.5 M $259 M
2021 Q1 73 43.3 M $286 M
2020 Q4 50 26.4 M $111 M
2020 Q3 45 28.0 M $134 M
2020 Q2 47 29.1 M $177 M
2020 Q1 49 29.3 M $161 M
2019 Q4 55 30.2 M $299 M
2019 Q3 51 21.7 M $125 M
2019 Q2 56 23.6 M $215 M
2019 Q1 56 24.0 M $333 M
2018 Q4 60 23.1 M $365 M
2018 Q3 37 19.5 M $378 M
2018 Q2 25 11.1 M $80.8 M
2018 Q1 25 10.7 M $32.9 M
2017 Q4 27 11.5 M $37.1 M
2017 Q3 23 10.1 M $48.9 M
2017 Q2 18 9.00 M $46.8 M
2017 Q1 21 9.06 M $45.3 M
2016 Q4 24 8.94 M $43.8 M
2016 Q3 25 8.69 M $58.0 M
2016 Q2 26 9.15 M $44.3 M
2016 Q1 29 9.63 M $46.9 M
2015 Q4 32 11.2 M $97.1 M
2015 Q3 38 11.9 M $173 M
2015 Q2 37 10.8 M $181 M
2015 Q1 38 11.0 M $241 M
2014 Q4 36 8.23 M $177 M
2014 Q3 30 7.63 M $130 M